ICM ADX-2191 injection

Phase 3

Aldeyra Therapeutics, Inc. (ALDX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

ALDXPhase 3$81M

ICM ADX-2191 injection Phase 3 Est. Readout

ICM ADX-2191 injection• Primary Vitreoretinal Lymphoma20

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Primary Vitreoretinal Lymphoma

View Full Landscape

Drug Information

Target Indication

Primary Vitreoretinal Lymphoma

Clinical Trial

NCT07402876

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ALDX

Aldeyra Therapeutics, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

ADX-102 OphthalmicPhase 3

Dry Eye Syndromes

Reproxalap OphthalmicPhase 3

Dry Eye Syndromes

ADX-2191 (intravitreal methotrexate)Phase 3

Proliferative Vitreoretinopathy

Reproxalap Ophthalmic Solution (Novel Formulation)Phase 3

Dry Eye

ADX-102 Topical Dermal Cream (reproxalap)Phase 3

Sjogren-Larsson Syndrome

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts